Matthew W. Davis
Known title: Chief Development OfficerCIK: 0002094283
Associated companies
Transaction History
| AQST | ▲ Buy | Grant | 50,000 | $0 | 3/9/2026 | View on chart |
| AQST | ▲ Buy | Grant | 50,000 | $0 | 11/10/2025 | View on chart |
| AQST | ▲ Buy | Grant | 50,000 | $0 | 3/9/2026 | View on chart |
| AQST | ▲ Buy | Grant | 50,000 | $0 | 11/10/2025 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Aquestive Therapeutics Appoints Richard Daly to Board
Aquestive Therapeutics announced the appointment of Richard Daly to its Board of Directors. This move is intended to strengthen the company's leadership and governance structure. The stock is currently trading within its 52-week range, with analysts maintaining an average price target of $9.33.
Aquestive Therapeutics Appoints Richard Daly to Board. Aquestive Therapeutics announced the appointment of Richard Daly to its Board of Directors. This move is intended to strengthen the company's leadership and governance structure. The stock is currently trading within its 52-week range, with analysts maintaining an average price target of $9.33.